Drug Study Triggers Flood of Suits

Plaintiffs firms around the U.S. are pouncing on Merck & Co. and Schering-Plough in the wake of revelations that a study by the two pharmaceutical giants found that their jointly produced anti-cholesterol medication, Vytorin, allegedly is no more effective than generic drugs costing less. All of the suits allege consumer fraud, claiming that the two companies delayed release of the study while they continued to say that the drug helped reduce the risk of heart attack. None claims personal injury.

This article requires premium access

This article requires premium access to Law.com. Please sign in or subscribe to read the full text.